Navigation Links
Quest International Announces They Will be First in US to Exhibit True 12-Bit Grayscale Mammographic Images
Date:4/3/2008

e us to look for areas for which we can bring new technologies and benefits," said Shawn Arshadi, President of Quest International, Inc.

"As a leading provider of Medical Displays we have worked together with OEMs and distributors on many integration projects. To be selected to work with both Apple and OsiriX developers from around the world is proof of the trust industry leaders have in Quest," said Bill Greenblatt, Vice President of Sales and Marketing at Quest International. "We are pleased to be part of the development team responsible for this breakthrough." Greenblatt continued by saying, "As Apple and OsiriX continue to evolve and develop medical applications, Quest will be here to support developers and users."

About Totoku

Totoku is a leading manufacturer of high-end medical image displays and touch panels. Founded in 1940 and in the display business since 1968, Totoku has supplied displays for various fields and has earned high marks for its product reliability.

About OsiriX

OsiriX provides an open-source, intuitive and user-friendly interface tailored for physicians. The platform has been designed to support peer-to-peer technology as an alternative to conventional Picture Archive and Communication Systems (PACS) architecture.

About Quest

Established in 1982, Quest International, Inc., is a leading provider of diagnostic imaging displays. Offering both off the shelf and customizable display solutions, Quest is the North American Master Distributor of the entire line of Totoku Medical displays. With resolutions of 1.3MP-5MP, Quest can support all grayscale and color display requirements. In addition, Quest is also an Value-Added Reseller of NEC Medical and Large Screen displays. Headquartered in Irvine, California and in operation 26 years, Quest is ISO 9001:2000 registered.

All names, product names and trademarks are property of their respective companies.


'/>"/>
SOURCE Quest International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... 2014 Using microscopic polymer light resonators that ... at MIT,s Quantum Photonics Laboratory have developed new ... parts-per-billion range. Optical sensors are ideal for detecting ... ratio, compact, lightweight nature, and immunity to electromagnetic ... been developed before, the MIT team conceived an ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2
... VMA, Confirms... -- LEUVEN, Belgium, September 1, 2010 ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... YORK, Aug. 31 Reportlinker.com announces that a ... catalogue: Women,s Infertility - Pipeline ... http://www.reportlinker.com/p0286181/Women,s-Infertility---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Women,s ... 2017 SummaryGlobalData, the industry analysis ...
... 31 Reportlinker.com announces that a ... in its catalogue: ... for Monoclonal Antibodies and Recombinant Proteins ... Production Technologies ...
Cached Biology Technology:Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 2Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 3Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 4Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 5Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 6Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 7Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 8Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 9Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 10Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 11
(Date:7/11/2014)... the City of Entiat on Tuesday, July 8, 2014. ... grew to over 1,000 acres by evening. Three outbuildings ... investigation by the Washington Department of Natural Resources. The ... in developing fire control strategies and tactics. Other cooperators ... of Natural Resources, (WA DNR), Bureau of Land Management, ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... Ume University, Sweden, have explored two different ways ... sequence leading to the formation of oxygen molecules ... in the scientific journal Nature Communications . ... day synthetic catalysts for water oxidation, which are ... the direct storage of solar energy in fuels ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... While endogenous estrogen (i.e., estrogen produced by ovaries and ... hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous ... risk, according to study results presented at the 33rd ... 8-12. "Our analysis suggests that, contrary to ...
... federal government, now fund the majority of human embryonic stem ... recent study in the journal Nature Biotechnology . ... they prioritized human embryonic stem cell research, and much of ... funded by the National Institutes of Health under federal guidelines ...
... Winter graduation deadlines have spurred a flurry of ... (STEM). However, for many women and students from underrepresented ... fellowship to faculty appointment in STEM is one of ... combat the loss of diversity in STEM fields, a ...
Cached Biology News:Estrogen alone is effective for reducing breast cancer risk 2States now fund majority of human embryonic stem cell research 2STEM workshop set to advance women, minorities 2
... The CHEMICON MDR1 Shift Assay provides a convenient ... occur upon transport of MDR1 substrates. Thus, the ... to which small molecules act as transport substrates ... in the presence of MDR1 substrates, the MDR1 ...
... wide and long electrophoresis hood ... gel documentation systems. Placed on ... camera in place and provides ... photography on the lab bench. ...
... Zyagen tissue microarrays are derived from Paraffin ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... on coated slides. Sections are large (3-5 ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
Biology Products: